These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26825639)

  • 1. The Cost-Effectiveness of the Integration of Nalmefene within the UK Healthcare System Treatment Pathway for Alcohol Dependence.
    Laramée P; Bell M; Irving A; Brodtkorb TH
    Alcohol Alcohol; 2016 May; 51(3):283-90. PubMed ID: 26825639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.
    Brodtkorb TH; Bell M; Irving AH; Laramée P
    CNS Drugs; 2016 Feb; 30(2):163-77. PubMed ID: 26879458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model.
    Laramée P; Brodtkorb TH; Rahhali N; Knight C; Barbosa C; François C; Toumi M; Daeppen JB; Rehm J
    BMJ Open; 2014 Sep; 4(9):e005376. PubMed ID: 25227627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M; Pandor A; Stevens JW; Rawdin A; Rice P; Thompson J; Morgan MY
    Pharmacoeconomics; 2015 Aug; 33(8):833-47. PubMed ID: 25851485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence.
    Laramée P; Millier A; Rahhali N; Cristeau O; Aballéa S; François C; Chalem Y; Toumi M; Rehm J
    Appl Health Econ Health Policy; 2016 Aug; 14(4):493-505. PubMed ID: 27283839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Nalmefene Added to Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol-Dependent Patients With High/Very High Drinking Risk Levels: A Microsimulation Model.
    Millier A; Laramée P; Rahhali N; Aballéa S; Daeppen JB; Rehm J; Toumi M
    J Stud Alcohol Drugs; 2017 Nov; 78(6):867-876. PubMed ID: 29087821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care.
    Castera P; Stewart E; Großkopf J; Brotons C; Brix Schou M; Zhang D; Steiniger Brach B; Meulien D;
    Eur Addict Res; 2018; 24(6):293-303. PubMed ID: 30485854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Benefits in reducing alcohol consumption: how nalmefene can help].
    Bendimerad P; Blecha L
    Encephale; 2014 Dec; 40(6):495-500. PubMed ID: 25454365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nalmefene. Alcohol dependence: no advance.
    Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
    Soyka M; Friede M; Schnitker J
    Pharmacopsychiatry; 2016 Mar; 49(2):66-75. PubMed ID: 26845589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nalmefene and its use in alcohol dependence.
    Gual A; Bruguera P; López-Pelayo H
    Drugs Today (Barc); 2014 May; 50(5):347-55. PubMed ID: 24918835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
    Mann K; Bladström A; Torup L; Gual A; van den Brink W
    Biol Psychiatry; 2013 Apr; 73(8):706-13. PubMed ID: 23237314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential.
    Soyka M
    Expert Opin Pharmacother; 2016; 17(4):619-26. PubMed ID: 26810044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT).
    UKATT Research Team
    BMJ; 2005 Sep; 331(7516):544. PubMed ID: 16150765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprosate, Using a Modeling Approach.
    Sluiter RL; Kievit W; van der Wilt GJ; Schene AH; Teichert M; Coenen MJH; Schellekens A
    Eur Addict Res; 2018; 24(5):245-254. PubMed ID: 30384381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Nalmefene: Exaggerated Expectations or Fallacy?
    Naudet F; Granger B; Braillon A
    Alcohol Alcohol; 2016 Sep; 51(5):623-4. PubMed ID: 27261473
    [No Abstract]   [Full Text] [Related]  

  • 17. A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders.
    Gastfriend DR
    Ann N Y Acad Sci; 2014 Oct; 1327(1):112-30. PubMed ID: 25236185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
    Gual A; He Y; Torup L; van den Brink W; Mann K;
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1432-42. PubMed ID: 23562264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for evaluating the economic value of drugs in alcohol dependence treatment.
    Schwappach D; Popova S; Mohapatra S; Patra J; Godinho A; Rehm J
    Drug Alcohol Depend; 2012 May; 122(3):165-73. PubMed ID: 21924845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
    van den Brink W; Strang J; Gual A; Sørensen P; Jensen TJ; Mann K
    Expert Opin Drug Saf; 2015 Apr; 14(4):495-504. PubMed ID: 25652768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.